Micals. Ann Rev Pharmacol Toxicol 2003; 43: 309?34. 15. Hu W, Sorrentino C, Denison MS, Kolaja K, Fielden MR. Induction of cyp1a1 can be a nonspecific biomarker of aryl hydrocarbon receptor activation: benefits of large scale screening of pharmaceuticals and toxicants in vivo and in vitro. Mol Pharmacol 2007; 71: 1475?486. 16. Secure S, Qin C, McDougal A. Improvement of selective aryl hydrocarbon receptor modulators for remedy of breast cancer. Expert Opin Investig Drugs 1999; 8: 1385?396. 17. Safe S, McDougal A. Mechanism of action and improvement of selective aryl hydrocarbon receptor modulators for treatment of hormone-dependent cancers (Evaluation). Int J Oncol 2002; 20: 1123?128. 18. O’Donnell EF, Kopparapu PR, Koch DC, Jang HS, Phillips JL, Tanguay RL et al. The aryl hydrocarbon receptor mediates leflunomide-induced growth inhibition of melanoma cells. PloS One particular 2012; 7: e40926. 19. O’Donnell EF, Saili KS, Koch DC, Kopparapu PR, Farrer D, Bisson WH et al. The antiinflammatory drug leflunomide is an agonist from the aryl hydrocarbon receptor. PLoS A single 2010; five: e13128. 20. Jones CD, Jevnikar MG, Pike AJ, Peters MK, Black LJ, Thompson AR et al. Antiestrogens. 2. Structure-activity research in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]phenyl]methanone hydrochloride (LY156758), a remarkably efficient estrogen antagonist with only minimal intrinsic estrogenicity. J Med Chem 1984; 27: 1057?066. 21. Clemens JA, Bennett DR, Black LJ, Jones CD. Effects of a brand new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. Life Sci 1983; 32: 2869?875. 22. Kleinberg DL, Todd J, Babitsky G. Inhibition by estradiol in the lactogenic effect of prolactin in primate mammary tissue: reversal by antiestrogens LY 156758 and tamoxifen. Proc Natl Acad Sci USA 1983; 80: 4144?148.Cell Death and DiseaseAhR-mediated apoptosis by raloxifene EF O’Donnell et al48.159611-02-6 Formula Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C.Price of Gemfibrozil 1-O-β-glucuronide A controlled trial of raloxifene (LY139481) HCl: influence on bone turnover and serum lipid profile in healthful postmenopausal girls. J Bone Miner Res 1996; 11: 835?42. 49. Boss SM, Huster WJ, Neild JA, Glant MD, Eisenhut CC, Draper MW. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol 1997; 177: 1458?464. 50. Taurin S, Allen KM, Scandlyn MJ, Rosengren RJ. Raloxifene reduces triple-negative breast cancer tumor development and decreases EGFR expression.PMID:33583335 Int J Oncol 2013; 43: 785?92. 51. Abagyan R, Totrov M, Kuznetsov D. ICM–A new strategy for protein modeling and design and style: applications to docking and structure prediction in the distorted native conformation. J Computat Chem 1994; 15: 488?06. 52. Tosh DK, Phan K, Gao ZG, Gakh AA, Xu F, Deflorian F et al. Optimization of adenosine 5′-carboxamide derivatives as adenosine receptor agonists applying structure-based ligand design and style and fragment screening. J Med Chem 2012; 55: 4297?308. 53. Totrov M, Abagyan R. Flexible protein-ligand docking by international energy optimization in internal coordinates. Proteins 1997; 29(Suppl 1): 215?20. 54. Kolluri SK, Zhu X, Zhou X, Lin B, Chen Y, Sun K et al. A short Nur77-derived peptide converts Bcl-2 from a protector to a killer. Cancer Cell 2008; 14: 285?98. 55. Li H, Kolluri SK, Gu J, Dawson MI, Cao X, Hobbs PD et al. Cytochrome c release and apoptosis induced by mitochondrial targe.